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Gain-of-function mutation in comple-
ment C2 protein identified in a patient
with aHUS
To the Editor:
The complement system, a basic defense mechanism of innate
immunity, protects us from invading pathogens and supports the
maintenance of body homeostasis.1 As proper functioning of
complement is based on the interplay between its activators and
inhibitors, functional impairment of a particular component often
leads to autoimmune or inflammatory diseases. The kidney is an
organ that is especially susceptible to complement-mediated
damage because of high blood flow combined with a delicate
structure of the filtrating barrier. Additionally, glomerular vessels
are vulnerable to thrombosis and damage by heme originating
from local hemolysis of red blood cells. Complement attack on
the kidney’s structures can be mediated by abnormalities in the
alternative complement pathway (AP).2 This route is constantly
active at a low level and spontaneously deposits C3 activation
fragments (C3b) on cell surfaces.1 Unlike pathogens, self-cells
are equipped with a panel of complement inhibitors that block
further pathway propagation. Therefore, the loss of control of
the AP is a condition permissive for complement-mediated dam-
age. The underlying mechanisms may involve aberrations that
render AP convertases insensitive to regulation. Such aberrations
include the presence of autoantibodies termed C3NeF, which sta-
bilize AP convertases (key enzymatic complexes that amplify the
complement cascade), autoantibodies binding to soluble comple-
ment inhibitors such as factor H, inheritance of rare variants of
membrane complement inhibitors (eg, CD46) and factor H, or
gain-of-function mutations in complement components such as
C3 or factor B (FB).2 Classical complement-mediated renal dis-
eases are C3 glomerulopathies (C3Gs) and atypical hemolytic
uremic syndrome (aHUS). There are reports suggesting that
next to dysregulation of the AP, abnormalities in the classical
pathway/lectin pathway (CP/LP) may also play a role in
pathogenesis. Previously, we screened 13 patients with C3G for
alterations increasing or prolonging convertase activity and found
1 individual with no acknowledged risk factors but antibodies sta-
bilizing the CP/LP convertases (C4NeF).3 Another screening of a
cohort of 168 patients with C3G revealed 3 patients who were
positive only for C4NeF autoantibodies whereas genetic analysis
showed no rare or novel variants of complement genes.4 Because
standard diagnostics of complement-mediated renal diseases has
thus far been focused on abnormalities in the AP, the possible role
of the CP/LP in pathogenesis may be underestimated. Up to now,
no gain-of-function variants within CP/LP convertase compo-
nents have been identified in patients. We decided to search for
such naturally occurring mutations in complement C2 protein
—a CP/LP analog and paralog of FB. These 2 proteins share a
high degree of amino acid similarity, as well as almost identical
length and structural organization.5 Therefore, it is highly prob-
able that they contain similar mutational hotspots, as already
demonstrated by translation of gain-of-function mutations in FB
to C2.6 Above all, the fact that pathogenic, naturally occurring
gain-of-function mutants of FB have already been characterized
encouraged us to look for analogous pathogenic mutations in C2.
DNA samples of 233 patients with aHUS and C3G who were
included in the Spanish aHUS/C3G Registry (https://www.
aHUSC3G.es) as of August 29, 2016, were analyzed for genetic
variants by using a next-generation sequencing panel that
included THBD, DGKE, and 42 complement genes. Missense
mutations in C2 gene were identified in 8 patients (Table I).
A complete list of analyzed genes, sequencing and data analysis
procedures, diagnostic criteria, and all methods used for further
characterization of mutated proteins are provided in this article’s
Online Repository (available in this article’s Online Repository at
www.jacionline.org).
Wild-type (WT) C2 and all mutants were expressed in the
eukaryotic system as C-terminal His-tagged proteins (see Fig E1,
A and B in this article’s Online Repository at www.jacionline.
org). Such modification does not affect the function of C2, as evi-
denced by a comparison of the hemolytic activity of WT and
plasma-purified C2 (see Fig E2, A and B in this article’s Online
Repository at www.jacionline.org). The variant Y347A, which
was designed in silico and experimentally confirmed as resistant
























31896638 rs367996721 1/233 c.G386A p.R129H HET aHUS HOM HOM None No — ANA
31901954 rs370121006 1/233 c. C727T p.R243C HET aHUS NO HET p.K591Sfs*10:
MASP1:HET
No — ANCA
31901976 rs150827255 1/233 c. C749G p. S250C HET aHUS HOM NO None — — —
31903804 rs9332739 11/233* c. G954C p. E318D All HET aHUS, C3GN — — — — — —
31910761 — 1/233 c. G1245C p. K415N HET aHUS NO HET None No — No
31910765 rs907804461 1/233 c. G1249C p. D417H HET C3GN HET NO None No No ANA
31911268 rs142802105 1/233 c. G1531A p. D511N HET C3GN HOM NO None No No No
31911573 — 1/233 c. T1720C p. S574P HET C3GN HET HET None No No ANA
ANA, Anti-nuclear antibody; ANCA, anti-neutrophil cytoplasm antibody; FH, factor H; HET, heterozygous; HOM, homozygous; ID, identifier; MCP, membrane cofactor
protein/CD46.
*Common polymorphism with a minor allele frequency greater than 0.01. The rest of the sequence variants display a minor allele frequency less than 0.001.
 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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FIG 1. Functional characteristics of recombinant C2 variants. A, Hemolytic assay using sensitized human
erythrocytes performed in C2-depleted human serum (DC2 serum) supplemented with a physiologic
concentration of specific C2 variants. B, The samemodel was used for analysis of CP/LP convertase activity.
C2 mutants were also tested by using the sensitized human lymphoma cell lines Ramos (C) and Raji (D) in a
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to CD55-, CD35- and C4BP-mediated convertase decay,6 was
included as a gain-of-function positive control.
Assays performed on sensitized human erythrocytes in C2-
depleted serum showed that the addition of each natural C2
mutant resulted in a lower hemolytic reaction (Fig 1, A) and lower
CP/LP convertase activity (Fig 1, B) than did the addition of WT
C2, except in the case of the variant S250C, which performed
similarly to Y347A. These results were confirmed in the cytotoxic
assay (Fig 1, C and D) and convertase assay (Fig 1, E and F) on
sensitized human lymphoma cell lines. The gain-of-function
S250C mutation did not affect C2 processing to C2a/C2b by
C1s enzyme (see Fig E3 in this article’s Online Repository at
www.jacionline.org). Unlike in experiments on human cells, the
activity of the S250C mutant was comparable to that of the WT
when tested in the same serum on sensitized sheep erythrocytes
(see Fig E4 in this article’s Online Repository at www.
jacionline.org). This led us to conclude that phenotype is depen-
dent on membrane-bound convertase inhibitors. Further analysis
of surface expression of these proteins (see Fig E5 in this article’s
Online Repository at www.jacionline.org) indicated CD55 as a
candidate, as confirmed by complement deposition assay in the
presence of CD55 ectodomain (see Fig E6 in this article’s Online
Repository at www.jacionline.org) and experiments with CD55-
KO Raji cells in which the gain-of-function phenotype of the
S250C mutant was lost (Fig 1, G and H). Serine 250 is highly
conserved within sequences of C2 and FB (see Table E1 in this
article’s Online Repository at www.jacionline.org), and accord-
ing to a model of C2a fragment (see Fig E7 in this article’s Online
Repository at www.jacionline.org), it is located only 22 A from
the Y347 residue, thus suggesting that these 2 residues together
could form a binding site for a single molecule of complement
inhibitor.
Genetic screening of patients in whom aHUS and C3G has
been diagnosed is usually limited to genes encoding AP
elements such as CFB, CFH, C3, CFI, and CD46. Here, we pre-
sent the first report of gain-of-function mutation in the CP/LP
convertase component found in human disease. Moreover,
S250C was the only rare variant in complement genes of a pa-
tient with aHUS who also carried the MCPggaac haplotype,
which decreases transcriptional activity of CD46 promotor re-
gion and dramatically increases penetrance of gain-of-function
mutation in FB.7 We propose that excessive activity of the
CP/LP convertases together with predisposing haplotypes and
environmental factors (eg, infections that increase the level of
C-reactive protein) form multiple hits that together precipitate
complement-related glomerulopathies. Therefore, routine diag-
nostics of such patients should not be focused only on the ab-
normalities in AP. We also underscore that commonly used
methods such as hemolysis of sheep erythrocytes may be
insufficient for functional analysis of gain-of-function variants
of complement proteins, as is likewise evidenced in Felberg
et al.8 The aHUS/C3G-causative nature of 7 C2 variants identi-
fied as loss-of-function mutants is less obvious than that of the
S250C variant. Low C2 activity may result in higher susceptibil-
ity to bacterial infections, which often precede disease epi-
sodes.9 However, the global minor allele frequency of the
E318D mutation (a common polymorphism identified as a
loss-of-function variant, which was the most frequent in our
cohort) is 0.0297 (ClinVar identifier 12130). Because the analo-
gous value in our cohort is lower (0.0236), we consider the rep-
resentation of this loss-of-function mutation as not exceeding
global distribution and probably not pivotal in the disease
pathomechanism.
For additional comments on the relevance and limitations of
our finding, please see this article’s Online Repository.
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complement-dependent cytotoxicity assay. Activation of CP in C3-depleted serum (DC3) or C5-depleted
serum (DC5) arrests the complement cascade at the stage of C3 CP/LP convertase or C5 CP/LP convertase,
respectively. E and F, Impact of selected C2 mutants added to such sera on the acticity of C3 CP/LP and C5
CP/LP convertases is shown. Raji CD55-knockout cells (G) and control Raji cells (H) were sorted to obtain
homogenous populations (islets on the right, with white and gray areas on histograms indicating cells
stained with isotype control and anti-CD55 antibody, respectively), which were used for
complement-dependent cytotoxicity assay in DC2 serum supplemented with selected C2 mutants. All
graphs show the results obtained from 3 independent experiments. Statistical significance of differences
between the given C2 variant and the WT was analyzed by using the Dunnett multiple comparison test
for nonrepeated measures. **P < .01; ***P < .001.
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Bitter perception is altered in asthma
and predicts its severity
To the Editor:
Despite a broad range of available treatment options, 5% to
10% of patients with asthma cannot achieve optimal disease
control. Taste receptors (TAS2Rs) in human airway smooth
muscle cells have been shown to cause bronchodilatation upon
activation.1,2 The expression of leukocyte TAS2Rs correlates
positively with asthma severity in both children and adults.3
This overexpression could be a compensation for the diminished
functionality of TAS2Rs. Association between TAS2R polymor-
phisms and severe asthma outcomes was also demonstrated.4 In
this clinical prospective study, we evaluated whether bitter taste
or n-propylthiouracil (PROP) sensitivity is altered in patients
with asthma, and whether this correlates with disease
characteristics.
A total of 127 adult participants were included: 65 patients with
asthma, confirmed through a pulmonologist, and 62 age- and sex-
matched volunteers without asthma. Exclusion criteria were age
less than 18 years and more than 60 years, presence of chronic
obstructive pulmonary disease, smoking history of more than 10
pack-years, and other conditions associated with taste loss, which
was defined as a diminished sensitivity to primary taste qualities:
bitter, sweet, salty, sour, and umami. Decrease in general taste
sense due to olfactory loss was not an exclusion criterion, because
the latter is associated with chronic rhinosinusitis, which is
frequent in the population with asthma. Participants rated their
smelling and tasting abilities on 10-cm visual analogue scales, an
asthma-specific questionnaire was completed to evaluate the
asthma control status (see p29, Box2-2A at ginasthma.org/gina-
reports),5 and the medication profile was assessed. Asthma
therapy step 1 to 5 was determined (see p44, Box 3-5 at ginasth-
ma.org/gina-reports).5 To account for broad distribution of
asthma control (43.1%, well controlled; 41.5%, partly controlled;
15.4%, uncontrolled asthma), asthma severity was evaluated,
with light and moderate asthma being well controlled with treat-
ment step 1/2 or 3/4, respectively, and severe asthma needing
treatment step 5 or being less than well controlled when treated
with step 4 or stepping down to 3.6 Latest percent predicted value
of FEV1, ratio FEV1/forced vital capacity, and presence of a diag-
nosed allergy, exercise-induced asthma, or Samter triad were
noted.
The gustatory sensitivity was assessed with the suprathreshold
‘‘Taste Sprays’’ test7 (perceived/not perceived) and the quasi-
threshold ‘‘Taste Strips’’ test (TST)8,9 for sweet, sour, bitter, salty,
and umami (0-4-point score per tastant; cumulative score, 0-20).
In addition, each patient and control subject was offered a paper
taste strip impregnated with PROP (Sensonics International,
Haddon Heights, NJ). Depending on whether PROP was
perceived as bitter or not, the participants were labeled as
‘‘tasters’’ or ‘‘nontasters.’’ Study population characteristics,
taste test scores, and asthma characteristics are summarized
in Tables E1 and E2 in this article’s Online Depository at
www.jacionline.org.
Patients with asthma had significantly lower sensitivity for
bitter, salty, and umami tastes and for PROP than healthy
volunteers (Mann-Whitney U test P 5 .026, P 5 .035, P < .001;
x2 [1, n 5 127] 5 11.53, P 5 .001, respectively). About 3.1%
of patients with asthma scored 0 in bitter TST (vs 0% by controls),
16.9% scored 1 (vs 0%), 12.3% scored 2 (vs 16.1%), 20% scored 3
(vs 22.6%), and 47.7% scored 4 (vs 61.3%). About 12.3% and
14.5% of patients in asthma and control groups, respectively,
took general medications with possible gustatory side effects
(MwPGSEs, eg, ramipril or sertraline). An additional 38.5% of
patients with asthma took asthma-specific MwPGSEs (eg, cetiri-
zine or formoterol). Taking theMwPGSEs had no influence on the
TST results in the asthma group (Mann-Whitney U test P >_ .28 in
all TSTs). To further investigate this relationship, the patients
with asthma were divided into 3 groups: (1) no MwPGSEs, (2)
asthma-specific MwPGSEs, and (3) other MwPGSEs. The
Kruskal-Wallis test revealed no significant difference in rated
and measured taste scores between the 3 groups in this scenario
(P > .35). In the control group, however, taking the MwPGSEs
had a significant impact with a moderate effect size on the results
of salty TST (Mann-Whitney U 5 60.5, Z 5 23.79, P < .001,
r 5 20.48) and cumulative TST (U 5 111.5, Z 5 22.56, P 5
.01, r520.33). Hence, there should be another, more potent fac-
tor in the patients with asthma that levels out the gustatory influ-
ence of drug side effects.
Spearman correlations between the results of taste tests and
other patients’ or control subjects’ parameters are presented in
Table E3 in this article’s Online Depository at www.jacionline.
org. The asthma treatment step (1-5 according to the Global
Initiative for Asthma classification, with 5 being the maximal
therapy) showed a negative correlation with the cumulative
TST score (r 5 20.26, P 5 .036) and with the bitter TST score
(r 5 20.3, P 5 .015, Fig 1, A). The asthma severity
graded with 1 for mild, 2 for moderate, and 3 for severe
asthma showed a negative correlation with the bitter TST score
(r 5 20.28, P 5 .026, Fig 1, B) and with the cumulative TST
score (r520.37, P5 .003). There was no significant correlation
between the results of the tests for other taste modalities and the
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METHODS
Diagnostic criteria of aHUS and C3G
Patients in whom aHUS was diagnosed fulfilled the following criteria:
platelet count less than 1503 109/L or a decrease ofmore than 25% frombase-
line values, hemolytic anemia, and serum creatinine level greater than the up-
per limit of the normal range, together with a negative Coombs test result,
normal activity of ADAMTS-13 and a negative Shiga toxin testing result.
C3G was diagnosed by renal biopsy, which in many cases included analysis
by electron microscopy. DNA from patients was analyzed for genetic variants
by using an in-house next-generation sequencingpanel including the following
44 genes:C1QA, C1QB, C1QC, C1R, C1S, C2, C3, C4A, C4BPA, C4BPB, C5,
C7, C8A, C8B, C8G, C9, CD46, CD55, CD59, CFB, CFD, CFH, CFHR1,
CFHR3, CFHR4, CFHR5, CFI, CFP, CLU, CR1, CR2, FCN1, FCN2, FCN3,
ITGAX, ITGB2, MASP1, MASP2, MBL2, SERPING1, VSIG4, and VTN.
Sequencing procedure and data analysis
Targeted sequences were captured by using the Nextera rapid capture
custom Enrichment Kit (Illumina, San Diego, Calif) and sequencing data
generated in a Miseq equipment using Miseq reagent kit v2 (300 cycles).
Sequence data were analyzed by using Burrows-Wheeler Alignment and
Picard software with additional filtering using customs tools. Variant calling
was performed both with bcftools and VarScan, and the variant calling files
generated were merged into a single file by using custom tools. Common
variants with a minor allele frequency value greater than 1% in any population
were excluded. To identified novel and/or pathogenic variants, we used
different databases (the Exome Aggregation Consortium database, Genome
Aggregation Database, 1000 Genomes, National Center for Biotechnology
Information Single-Nucleotide Polymorphism Database, aHUS Mutation
Database [www.fh-hus.org], or our in-house database). Pathogenicity was es-
tablished by using multiple functional prediction methods (SIFT, PolyPhen2,
etc) included in the ANNOVAR server and the functional data available in our
laboratory and in the literature. Variants were categorized as pathogenic, var-
iants of uncertain significance, and benign. The analysis of copy number var-
iations within the CFH-CFHR gene region was performed by multiplex
ligation-dependent probe amplification with the P236 A1 ARMD mix 1
(MRC-Holland, Amsterdam, The Netherlands).
Cell lines
The human lymphoma cell lines Raji and Ramos (both obtained from the
American Type Culture Collection, Manassas, Va) were cultured in RPMI
1640 medium with l-glutamine (Mediatech, New York, NY) supplemented
with 10% FBS (PANBiotech, Aidenbach, Germany). Cells were cultivated at
378C and humidified in a 5%CO2 atmosphere. Raji cells with CD55 knockout
were produced by clustered regularly interspaced short palindromic repeats/
Cas9 technology as described in Thielen et al.E1
Protein expression, purification, and analysis
Wild-type C2 cDNA sequence (accession number NM_000063) addition-
ally containing 6 histidine codons at the 39 terminus, as well as sequences for
R129H, R243C, S250C, E318D, K415N, D417H, D511N, S574P, and Y347A
variantswere codon-optimized, synthesized, and cloned into a pCEP4vector in
the framework of GeneArtGene Synthesis service by Thermo Fisher Scientific
(Waltham,Mass). Proteins were expressed in a eukaryotic system and purified
as described in Urban et al.E2 Western blotting was developed with anti-C2
antibody (Complement Technology, Tyler, Tex) diluted 1:1,000, followed by
horseradish peroxidase (HRP)-conjugated donkey anti-goat antibody diluted
1:10,000 (Jackson ImmunoResearch, Cambridgeshire, United Kingdom).
Hemolysis-based assay
Hemolytic assays evaluating the activity of recombinant, his-tagged C2
mutants were performed as described previously,E3 with some modifications.
Sheep erythrocytes (Biomaxima, Gdansk, Poland) were sensitized with ambo-
ceptor (Behring Bern, Switzerland) diluted 1:1000 in 1 mL of dextrose-
gelatin-Veronal buffer (DGVB111) for 20 minutes at 378C.E3 Human
erythrocytes were sensitized with anti-human red blood cells antibodies
(Rockland, Limerick, Pa) diluted 1:75. Afterward, cells were washed 3 times,
pelleted, and resuspended in 1 mL of DGVB11. Ten microliters of these sus-
pensions were overlaid with serial dilutions of C2-depleted serum (DC2)
(Complement Technology) in DGVB11 supplemented with the particular
C2 mutant and incubated for 30 minutes at 37oC. Erythrocytes were centri-
fuged, and the hemoglobin released to the supernatant was measured at 405
nm in a Synergy H1 microplate reader (Biotek, Winooski, Vt). For the CP/
LP convertase activity assay, sensitized erythrocytes were mixed with 2.5
mg/mL of the C5 inhibitor OmCI.E3 The plate was incubated at 37oC, and
2% of the C2-depleted serum mixed with a particular C2 mutant diluted in
DGVB11 was added at the indicated time points. Then, the erythrocytes
were washed with EDTA–gelatin-Veronal buffer (GVB),E3 pelleted, overlaid
with EDTA-GVB containing 1:40 dilution of guinea pig serum (Harlan Lab-
oratories, Itingen, Switzerland), and incubated for 30 minutes at 37oC. Lysis
was determined by measuring the absorbance at 405 nm. The readout of the
sample of erythrocytes mixed with water was considered as 100% (full) lysis.
CDC assay
Complement-dependent cytotoxicity (CDC) was measured by calcein
release assay as described in Stasilojc et al,E4 butDC2 serum was used instead
of normal human serum. Cell lysis was calculated in reference to the fluores-
cence readout (490/520 nm) obtained for the supernatant of cells treated with
2% NP40 (full lysis).
CP/LP convertase assays on CD201 cells
Ofatumumab (100 mg/mL) and 30% of the C5- or C3-depleted serum
(Complement Technology) supplemented with 7.5 mg/mL of the analyzed C2
variantwereadded tocalcein-loadedcells at the indicated timepoints.Complement
activation in these conditions was arrested at the stage of C3 CP/LP convertase or
C5 CP/LP convertase, respectively. Then, cells were washed with EDTA-GVB
buffer, pelleted, and overlaidwithEDTA-GVBcontaining a 1:20dilutionof guinea
pig serum followedby a 30-minute incubation (37oC, 600g). Fluorescence readout
was performed as already described in the section on CDC assay.
Cleavage of C2 with C1s enzyme
EachC2mutantwas incubated for2hourswith4nMC1senzyme(Complement
Technology) diluted in 5mMveronal buffer supplementedwith 1mMofCa21 and
Mg21. Cleavage into C2a and C2b was analyzed by Western blot. C2 polyclonal
goat anti-human antibody (No. A212, Complement Technology) diluted 1:1,000
and secondary donkey anti-goat antibody conjugated with HRP (Jackson
ImmunoResearch) diluted 1:10,000 were used for detection, followed by 3,3’
-diaminobenzidine (Vector Laboratories, Burlingame, Calif) applied for
visualization.
C3b microplate deposition assay
ELISA plates were coated with 50 mg/mL of human immunoglobulin
solution (Pentaglobin, Biotest) for 1 hour at 37oC and then blocked for 30 mi-
nutes with 3% fish gelatin (Sigma). Afterward, the plates were incubated with
0.5% DC2 serum and the particular C2 variant was diluted in GVB with or
without the addition of soluble ectodomain of CD55 inhibitor (produced as
described in Okroj et alE5) for 1 hour at 37oC. C3b detection was performed
with polyclonal goat-anti human C3 antibody (Complement Technology), fol-
lowed by rabbit anti-goat antibody conjugated with HRP (Dako, Glostrup,
Denmark) diluted 1:10,000 and 1:5,000 in PBS, respectively. The assay was
developed by using o-phenylenediamine dihydrochloride (Sigma Aldrich,
Darmstadt, Germany) according to manufacturer’s instructions.
Evaluation of complement regulatory proteins
Expression of CD35, CD46, and CD55 in CD201 cells and human eryth-
rocytes was assessed by flow cytometry as described in Okroj et al.E6 Primary
antibodies (clone UJ11 for CD35, clone MEM-258 for CD46, and clone HI-
55a for CD55) and isotype controls were purchased from Immunotools
(Friesoythe, Germany).
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Assessment of amino acid conservation in C2
protein
Amino acids sequences of C2 and FB proteins were retrieved from the
UniProtE7 amino acids sequence database searched for the term complement
C2, and the results were further manually filtered out to obtain only sequences
of C2 and FB proteins. For further analysis, 151 sequences were selected. All
selected sequences were subjected to multiple sequence alignment by using a
multiple alignment using fast Fourier transform algorithm.E8
Statistical analysis
Statistical calculations were performed with GraphPad Prism 7 software
(GraphPad Software Inc, San Diego, Calif). The Kruskal-Wallis test was
applied for column analysis (see Fig E3). The Dunnett multiple comparison
test for nonrepeated measures was applied for grouped analysis (see Figs
E1, E2, and E4-E7).
RELEVANCE AND LIMITATIONS OF OUR FINDING
Importance of clinical data analysis
The domain structure of FB and complement C2 share a high
degree of similarity.E10 The vonWillenbrand type A domain of FB
contains severalmutational hot spots, alterations ofwhichmay pro-
voke a potentially pathogenic gain-of-function phenotype.E11,E12
We identified 1 rare variant of C2 with mutation at conserved posi-
tion 250 adjacent to a-helixes forming the von Willenbrand type
A domain, which leads to the formation of hyperactive CP/LP con-
vertases. No previous studies have shown the importance of this po-
sition for the biologic activity of C2 or FB. Moreover, no prior
studies have presented patients with gain-of-function mutations in
complement genes coding for CP/LP convertase components.
Thus, to the best of our knowledge, this is the first such report
confirmed by functional studies. Genetic screening in patients in
whom aHUS and C3G have been diagnosed is usually limited to
genes encoding AP elements such as FB, CFH, C3, CFI, and
CD46,E13 and on the basis of this scheme, abnormalities in comple-
ment are found in 70% of patients with aHUSwhereas 30% remain
unexplained.E14 Typically, patients with aHUS are heterozygous in
complement mutations, and the same mutation can be carried by
healthy relatives. Often, the difference between healthy relatives
carrying pathogenic mutations and patients is the presence of pre-
disposing polymorphisms in genes coding complement regula-
tors.E15-E17 Moreover, aHUS can be preceded by bacterial and
viral infections, surgical procedures, use of certain medications,
and pregnancy inwomen.E18,E19 One of the limitations of our study
is the lack of a medical record for the patient with aHUS who was
carrying the S250C allele, which was not available. Such detailed
clinical data, aswell as the familyhistory and agenotype/phenotype
analysis of family members, would help to evaluate whether this
case is similar to or different from cases of aHUS connected to
gain-of-function mutations in FB or C3 proteins. On the other
hand, it is highly plausible that overactive CP/LP convertases are
responsible for the percentage of aHUS cases previously classified
as being of unknown etiology.
Possible stimuli of CP/LP in S250C carriers and
potential diagnostic/therapeutic directions
Unlike AP, CP and LP require specific stimuli (eg, antibodies,
certain sugar moieties, or C-reactive protein.E20 Therefore, 2 con-
ditions permissive for CP/LP-mediated autoimmune disease are
necessary, namely, loss of proper pathway regulation (eg,
formation of decay-resistant CP/LP convertase) and presence of
stimuli driving the pathway. Without a detailed clinical report,
we can only speculate on a hypothetical explanation of disease
development in the patient with the 250C mutation. Nonetheless,
infections and presence of autoantibodies (or appearance of anti-
bodies cross-reactive to patient cells and/or tissues) emerge as
possible drivers of pathomechanism. In line with reports on
C4NeF as the only complement abnormality found in patients
with C3G,E21,E22 we postulate that analysis of CP/LP convertase
activity should be included in routine diagnostic procedures for
use with patients with aHUS and C3G. Patients with known CP/
LP gain-of-function mutations should be closely monitored dur-
ing infections for first signs of aHUS/C3G so that therapy can
be started as early as possible to limit renal damage. Also, thera-
peutic intervention in patients with gain-of-function mutations in
LP/CP may theoretically target pathway stimuli (eg, production
of C-reactive protein, source of autoantibodies) and become an
alternative for eculizumab (Soliris), which is among the most
expensive drugs.
Relevance of loss-of-function mutations in C2
Seven of 233 patients had mutations in C2 resulting in low CP
hemolytic activity and no other rare variant in their complement
genes (except for the carrier of the R243Cmutation, which caused
complete loss of CP activity) (Table I, Fig 1, A and B, and Fig E3).
The causative nature of these variants for aHUS/C3G is less
obvious than that of S250C. Because the low physiologic concen-
tration of C2 makes it a bottleneck of CP/LP, such patients may
have impaired clearance of bacteria. Indeed, the E318D mutation
identified in 11 of 233 patients from our cohort was previously
associated with an increased rate of pneumonia in patients with
trauma.E23 Infections with non–Shiga toxin-producing Escheri-
chia coli (a causative factor of ‘‘typical’’ HUS)E24 and strains
such as Streptococcus pneumoniae, Pseudomonas aeruginosa,
or Bordetella pertussisE24-E28 often precede aHUS/CG3 episodes;
however, genetic predisposition to infections and connotations of
aHUS/C3G were not intensively investigated. Functional impair-
ment of C2 may possibly influence this aspect, but this has to be
confirmed by separate epidemiologic studies. Nonetheless, on the
one hand, genetic C2 deficiency is among the most common com-
plement deficiencies, with the occurrence of 1:20.000 homozy-
gous carriersE29; on the other hand, there is a limited number of
reports describing the prevalence of missense C2 mutants and
no prior data on their functional characteristics.
Structure-function relationship of S250C mutant
Serine-to-cysteine substitution is considered to be one of the
most conservative changes possible between any pair of amino
acid residues in proteins, as they differ only at the g-atom and
have similar side-chain volumes.E30 Therefore, the fact that
S250C exchange has a profound impact on the function of C2 is
surprising. However, there are studies elaborating on a bigger
atomic radius of sulfur in a cysteine than the radius of oxygen
in the serine and its impact on hydrogen-bonding propensities,
hydrophobicity, and packing, all of which can trigger
conformational changes in proteins and affect their biologic func-
tions.E30,E31 On the other hand, introduction of free cysteine at the
surface of the protein can result in the formation of homodimers
or heterodimers with other ubiquitous proteins, as well as in the
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formation of adducts with low-molecular-weight chemical en-
tities (eg, glutathione).Western blot analysis of S250Cmutant un-
der nonreducing conditions showed no obvious bands above the
peak of the full-length protein (103 kDa [Fig E1]). Mass spec-
trometry analysis focused at the area between 102 and 104 kDa
(data not shown) revealed the existence of 3 isoforms within the
full length WTand S250C proteins (probably because of changes
in glycosylation), thus making it difficult to establish a definitive
conclusion regarding molecular weight differences.
REFERENCES
E1. Thielen AJF, van Baarsen IM, Jongsma ML, Zeerleder S, Spaapen RM, Wouters
D. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as
a tool for complement research. J Immunol Methods 2018;456:15-22.
E2. Urban A, Borowska A, Felberg A, van den Heuvel L, Stasilojc G, Volokhina E,
et al. Gain of function mutant of complement factor B K323E mimics pathogenic
C3NeF autoantibodies in convertase assays. Autoimmunity 2018;51:18-24.
E3. Blom AM, Volokhina EB, Fransson V, Stromberg P, Berghard L, Viktorelius M,
et al. A novel method for direct measurement of complement convertases activity
in human serum. Clin Exp Immunol 2014;178:142-53.
E4. Stasilojc G, Felberg A, Urban A, Kowalska D, Ma S, Blom AM, et al. Calcein
release assay as a method for monitoring serum complement activity during
monoclonal antibody therapy in patients with B-cell malignancies. J Immunol
Methods 2020;476:112675.
E5. Okroj M, Mark L, Stokowska A, Wong SW, Rose N, Blackbourn DJ, et al. Char-
acterization of the complement inhibitory function of rhesus rhadinovirus com-
plement control protein (RCP). J Biol Chem 2009;284:505-14.
E6. Okroj M, Eriksson I, Osterborg A, Blom AM. Killing of CLL and NHL cells by
rituximab and ofatumumab under limited availability of complement. Med Oncol
2013;30:759.
E7. Boutet E, Lieberherr D, Tognolli M, Schneider M, Bansal P, Bridge AJ, et al. Uni-
ProtKB/Swiss-Prot, the manually annotated section of the UniProt Knowledge-
Base: how to use the entry view. Methods Mol Biol 2016;1374:23-54.
E8. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7:
improvements in performance and usability. Mol Biol Evol 2013;30:772-80.
E9. Milder FJ, Raaijmakers HC, Vandeputte MD, Schouten A, Huizinga EG, Romijn
RA, et al. Structure of complement component C2A: implications for convertase
formation and substrate binding. Structure 2006;14:1587-97.
E10. Krishnan V, Xu Y, Macon K, Volanakis JE, Narayana SV. The structure of C2b, a
fragment of complement component C2 produced during C3 convertase forma-
tion. Acta Crystallogr D Biol Crystallogr 2009;65:266-74.
E11. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA,
Garrido CA, et al. Gain-of-function mutations in complement factor B are asso-
ciated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007;
104:240-5.
E12. Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, et al. Comple-
ment factor B mutations in atypical hemolytic uremic syndrome-disease-relevant
or benign? J Am Soc Nephrol 2014;25:2053-65.
E13. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J
Rare Dis 2011;6:60.
E14. Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome.
Curr Opin Pediatr 2013;25:209-15.
E15. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role
of genetic complement abnormalities in sporadic and familial aHUS and their
impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-59.
E16. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, Lopez-
Trascasa M, Sanchez-Corral P, et al. Predisposition to atypical hemolytic uremic
syndrome involves the concurrence of different susceptibility alleles in the regu-
lators of complement activation gene cluster in 1q32. Hum Mol Genet 2005;14:
703-12.
E17. Fremeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey MA, Strain L, Loirat
C, et al. The development of atypical haemolytic-uraemic syndrome is influenced
by susceptibility factors in factor H and membrane cofactor protein: evidence
from two independent cohorts. J Med Genet 2005;42:852-6.
E18. Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V,
Goodship TH, et al. Atypical aHUS: state of the art. Mol Immunol 2015;67:
31-42.
E19. Jokiranta TS. HUS and atypical HUS. Blood 2017;129:2847-56.
E20. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for
immune surveillance and homeostasis. Nat Immunol 2010;11:785-97.
E21. Blom AM, Corvillo F, Magda M, Stasilojc G, Nozal P, Perez-Valdivia MA, et al.
Testing the activity of complement convertases in serum/plasma for diagnosis of
C4NeF-mediated C3 glomerulonephritis. J Clin Immunol 2016;36:517-27.
E22. Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes G, et al. C4
nephritic factors in C3 glomerulopathy: a case series. Am J Kidney Dis 2017;70:
834-43.
E23. Morris JA Jr, Francois C, Olson PK, Cotton BA, Summar M, Jenkins JM, et al.
Genetic variation in complement component 2 of the classical complement
pathway is associated with increased mortality and infection: a study of 627 pa-
tients with trauma. J Trauma 2009;66:1265-70, [discussion: 70-2].
E24. Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern
Med 2017;281:123-48.
E25. Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC. A new
era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth
J Med 2012;70:121-9.
E26. Obando I, Camacho MS, Falcon-Neyra D, Hurtado-Mingo A, Neth O. Atypical
hemolytic uremic syndrome associated with Bordetella pertussis infection. Pe-
diatr Infect Dis J 2012;31:1210.
E27. Chaturvedi S, Licht C, Langlois V. Hemolytic uremic syndrome caused by Bor-
detella pertussis infection. Pediatr Nephrol 2010;25:1361-4.
E28. Pela I, Seracini D, Caprioli A, Castelletti F, Giammanco A. Hemolytic uremic
syndrome in an infant following Bordetella pertussis infection. Eur J Clin Micro-
biol Infect Dis 2006;25:515-7.
E29. Truedsson L. Classical pathway deficiencies - a short analytical review. Mol Im-
munol 2015;68:14-9.
E30. Santos J, Risso VA, Sica MP, Ermacora MR. Effects of serine-to-cysteine muta-
tions on beta-lactamase folding. Biophys J 2007;93:1707-18.
E31. He JJ, Quiocho FA. A nonconservative serine to cysteine mutation in the sulfate-
binding protein, a transport receptor. Science 1991;251:1479-81.
J ALLERGY CLIN IMMUNOL
VOLUME 146, NUMBER 4
LETTERS TO THE EDITOR 919.e3
FIG E1. Purification of recombinant C2 variants. A, Purified C2 proteins were run on SDS-PAGE under
reducing conditions and stained with Coomassie blue. Lanes were purposely overloaded to visualize impu-
rities. B, Western blotting of purified WT and S250C C2 proteins under reducing and nonreducing condi-
tions. Western blotting of S250C was performed to visualize any homodimers or heterodimers, which
could arise as a result of introduction of cysteine. However, there were no additional bands above 100 kDa.
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FIG E2. Assessment of his-tag influence on activity of C2 protein. A, Comparison of hemolytic activity of re-
combinant WT C2 protein and serum-purified C2. Proteins were added to C2-depleted serum (DC2) at their
physiologic concentrations. Assay was performed in sensitized sheep erythrocytes. B, Comparison of he-
molytic activity of DC2 serum reconstituted with recombinant WT C2 and normal human serum (NHS), as
performed on sensitized human erythrocytes.
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FIG E3. Cleavage of C2 variants by C1s enzyme. Representative Western
blot (top panel) and associated densitometric analysis (bottom panel) pre-
sent formation of C2a and C2b after a 2-hour incubation with 4 nM C1s of
each C2 variant. The graph shows the results from 3 independent experi-
ments. Triple asterisk denotes statistical significance versus plasma-
purified C2 at a value of P less than .001 according to the Kruskal-Wallis test.
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FIG E4. Convertase assay on sensitized sheep erythrocytes. CP/LP con-
vertase activity assay performed on sensitized sheep erythrocytes mixed
with DC2 serum supplemented with the particular C2 variant.
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FIG E5. Expression of complement inhibitors on cell surface. Expression of CD35, CD46 (compared with
isotype control mouse IgG1), and CD55 (compared with isotype control mouse IgG2a) on human
erythrocytes, Raji cells, and Ramos cells.
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FIG E6. C3b deposition in the presence of soluble ectodomain of CD55. The
graph presents C3b production and deposition on a microplate. Next, 0.5%
of the DC2 serum supplemented with a particular C2 mutant was incubated
for 1 hour on a plate coated with aggregated human IgG. Results show the
level of C3b deposition relative to WT C2 with no soluble CD55 ectodomain
added. Serum alone (DC2) was applied as a negative control. Double
asterisks and triple asterisks denote statistical significance at P values of
<.01 and <.0001, respectively, according to the Dunnett multiple compari-
son test for nonrepeated measures.
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FIG E7. Model of C2a fragment. The structure (2 views) of C2b protein is based on Protein Data Bank record
2I6Q.E9 The vonWillebrand factor A-type domain is shown in red, and the C-terminal trypsin-like serine pro-
teinase domain is shown in green. Positions of the mutated residues are shown in blue; residues S250 and
Y347 are labeled.
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TABLE E1. Occurrence (in percent) of the most frequent amino
acid types in selected positions
Analyzed amino acids
position in H sapiens C2
protein sequence studied
in this work
Occurrence of the most
frequent amino acid





E318 52% E, 30% W
Y347 75% Y, 15% H
K415 31% P, 24% K, 23% N
D417 39% D, 37% V, 11% E
D511 29% V, 17% D, 17% N,
13% H
S574 69% S, 18% D
Presented data are based on multiple sequence alignment of 151 C2 and Factor B
amino acid sequences.
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